Free Trial
NASDAQ:TXMD

TherapeuticsMD Q1 2024 Earnings Report

TherapeuticsMD logo
$1.10 +0.02 (+1.85%)
As of 02:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TherapeuticsMD EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TherapeuticsMD Revenue Results

Actual Revenue
$0.31 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TherapeuticsMD Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Friday, May 10, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

TherapeuticsMD's Q2 2025 earnings is scheduled for Monday, August 11, 2025

TherapeuticsMD Earnings Headlines

379 passengers walked away from this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

View TherapeuticsMD Profile

More Earnings Resources from MarketBeat